Fighting Cancer and Infectious Diseases KUPANDO is a pioneering Berlin-based biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity. Our Mission is … to provide, not only a safe but also affordable, immunotherapy to cancer patients, and to develop immunostimulatory agents with the means to prevent infectious diseases. TLR 4/7 AGONIST Drug Candidate […]
Location: Germany
Employees: 1-10
Total raised: $25.85M
Founded date: 2018
Investors 1
| Date | Name | Website |
| 27.09.2022 | BFB Brande... | brandenbur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 19.03.2026 | Series A | $11.69M | High-Tech ... |
| 01.10.2022 | Series A | $14.16M | - |
Mentions in press and media 7
| Date | Title | Description |
| 19.03.2026 | German Biotech Kupando Secures €10M for Advanced Immunotherapy Pipeline | Kupando, a prominent German biotech firm, recently announced substantial new financing. The company secured an additional €10 million in Series A funding. This latest capital infusion elevates its total Series A funding to €23 million. The ... |
| 19.03.2026 | Kupando: €10 Million Series A Extension Raised By Biotech Company To Advance Immunotherapy Programs | Kupando, a Germany-based biotech company developing therapies for cancer and infectious diseases, has raised an additional €10 million in Series A funding, bringing the total to approximately $23 million. The financing was co-led by Remiges... |
| 18.03.2026 | Inspired by animal immunity, Germany’s Kupando raises €10 million for cancer therapy | Schönefeld-based Kupando, a biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained immunity for use in oncology and infectious diseases, has secured an additional €10 million in Series A f... |
| 18.03.2026 | Kupando Raises Additional €10M in Series A Funding | Kupando, a Schönefeld, Germany-based biotech company developing therapies for cancer and infectious diseases, raised additional €10M in Series A funding. The round was co-led by Remiges Ventures, and LifeCare Partners, with participation fr... |
| 01.10.2022 | Kupando raises €13 million in Series A funding round | |
| 26.09.2022 | Kupando Raises €13M in Series A Funding | Kupando, a Schoenefeld, Germany-based biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases, closed a €13m Series A funding. The round was led by Remiges Ventures an... |
| - | Kupando | “Kupando – Fighting Cancer and Infectious Diseases. KUPANDO is a pioneering Berlin-based biopharmaceutical company.” |